Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

EMERGENT BIOSOLUTIONS INC.

(EBS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Covid-19 Vaccine Maker Blames Problems on Producing Two Different Shots -- Update

05/19/2021 | 10:39am EDT

By Peter Loftus

Emergent BioSolutions Inc. has made enough of a key ingredient to yield more than 100 million doses of Johnson & Johnson's Covid-19 vaccine, and federal health regulators are evaluating whether to release the shots, Emergent's chief executive said.

Emergent CEO Robert Kramer apologized during a congressional hearing Wednesday for the problems at the company's Baltimore plant that resulted in the contamination earlier this year of a batch of the vaccine.

Mr. Kramer said the company, which makes vaccines and drugs under contract, has been taking corrective steps to fix the manufacturing problems at the plant.

Emergent has blamed some of the problems at the plant on having to produce two Covid-19 vaccines at large scale, which the company said strained the capacity of its equipment.

Emergent described some of the problems and its plan to fix them in a letter to the U.S. Food and Drug Administration, responding to the agency's finding of various deficiencies during an April inspection.

A subcommittee of the U.S. House Committee on Oversight and Reform released the April 30 letter ahead of its hearing about Emergent.

Emergent was producing a bulk key vaccine ingredient for Johnson & Johnson's Covid-19 vaccine, but a mishap led to the contamination of material that could have yielded up to 15 million doses during January and February.

The contamination came from viral material similar to what was used in the production of AstraZeneca PLC's Covid-19 vaccine at the same plant, according to a memo from the Democratic staff of the House committee to members.

The incident ruined the batch of J&J's vaccine ingredient and led to a halt in production of the J&J vaccine, as well as a decision to relocate production of AstraZeneca's vaccine elsewhere. In addition, J&J took over manufacturing at the Emergent plant.

At the hearing, Mr. Kramer said the company agreed last year with the federal government to manufacture both J&J's and AstraZeneca's vaccines, though the plant hadn't previously produced vaccines at full capacity.

"Ramping up production of two novel vaccines on a very large scale in the same facility is unprecedented," he said in remote online testimony.

The FDA's inspection of the Emergent plant found it didn't maintain clean, sanitary conditions and didn't take proper steps to prevent contamination. The inspection found the building and equipment, including refrigerators, weren't big enough to support large-scale manufacturing in a way that would ensure clean conditions.

Emergent, in its April 30 response, said: "The sudden scale-up to full-scale manufacturing activities for two different Covid-19 vaccine drug substances strained the capacity of Emergent's" refrigerators.

The company said it has cleaned and organized them and will purchase additional refrigerators.

The company also said its plant "experienced a dramatic increase in storage and staging demands as the facility operated at full capacity for the first time." The company said it has changed procedures to mitigate the risk of contamination.

Emergent, based in Gaithersburg, Md., said in a statement Wednesday that its role in responding to the Covid-19 pandemic is "unlike any we have confronted before." The company said it is focused on releasing a vaccine ingredient that is currently under evaluation and on resuming vaccine production.

The House committee also released documents showing that Emergent has charged the federal government $27 million a month in reservation fees to be ready to manufacture vaccines.

The government has paid Emergent $271 million of these fees to date, but has partially stopped payment since learning of the contamination, the committee's Democratic staff said in the memo to members.

Write to Peter Loftus at peter.loftus@wsj.com

(END) Dow Jones Newswires

05-19-21 1239ET

Stocks mentioned in the article
ChangeLast1st jan.
APPIAN CORPORATION -0.34% 125.77 Delayed Quote.-22.14%
ASTRAZENECA PLC 0.25% 8480 Delayed Quote.15.78%
DJ INDUSTRIAL 0.68% 35061.55 Delayed Quote.13.78%
EMERGENT BIOSOLUTIONS INC. 1.16% 64.39 Delayed Quote.-28.14%
JOHNSON & JOHNSON 1.06% 171.79 Delayed Quote.9.16%
All news about EMERGENT BIOSOLUTIONS INC.
07/22EMERGENT BIOSOLUTIONS INC. : Change in Directors or Principal Officers (form 8-K..
AQ
07/22Emergent Biosolutions Inc. Announces Adam Havey Expands Role to Executive Vic..
CI
07/21J&J forecasts $2.5 billion in 2021 COVID-19 vaccine sales, sets lower product..
RE
07/15EMERGENT BIOSOLUTIONS : to Release Second Quarter 2021 Financial Results and Con..
AQ
07/14EMERGENT BIOSOLUTIONS : Gets $182 Million Smallpox Vaccine Supply Contract Exten..
MT
07/14EMERGENT BIOSOLUTIONS INC. : Entry into a Material Definitive Agreement (form 8-..
AQ
07/14Emergent Biosolutions Inc Receives A Contract Modification from the Office of..
CI
07/05THE U.S. FOOD AND DRUG ADMINISTRATIO :
AQ
07/02ASTRAZENECA : U.S. authorizes additional batch of J&J COVID-19 vaccine produced ..
RE
06/25EMERGENT BIOSOLUTIONS INC.(NYSE : EBS) added to Russell 2500 Value Index
CI
More news
Financials (USD)
Sales 2021 1 793 M - -
Net income 2021 377 M - -
Net Debt 2021 71,2 M - -
P/E ratio 2021 9,37x
Yield 2021 -
Capitalization 3 450 M 3 450 M -
EV / Sales 2021 1,96x
EV / Sales 2022 2,14x
Nbr of Employees 2 200
Free-Float 88,6%
Chart EMERGENT BIOSOLUTIONS INC.
Duration : Period :
Emergent BioSolutions Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EMERGENT BIOSOLUTIONS INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 64,39 $
Average target price 86,17 $
Spread / Average Target 33,8%
EPS Revisions
Managers and Directors
Robert G. Kramer President, Chief Executive Officer & Director
Richard Scott Lindahl Chief Financial Officer, Treasurer & Executive VP
Fuad El Hibri Executive Chairman
Sharon M. Solomon Chief Information Officer & Senior Vice President
Karen L. Smith Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
EMERGENT BIOSOLUTIONS INC.-28.14%3 396
JOHNSON & JOHNSON9.16%432 430
ROCHE HOLDING AG12.39%325 975
PFIZER, INC.13.23%218 198
ELI LILLY AND COMPANY44.60%209 276
NOVARTIS AG1.10%207 246